argenx SE（ARGX）資訊與事件

$1,023.210

-34.482 (-3.37%)收盤時

ARGX 資訊

Latest Ratings and Outlook from Wall Street

Argenx Achieves Phase 3 Success for Vyvgart Hytrulo in Autoimmune Myositis

Argenx's Vyvgart Hytrulo Shows Positive Phase 3 Results for Autoimmune Myositis

Biotech Stocks Reach 52-Week Highs Amid Positive Trials

Zai Lab and argenx Announce Positive ALKIVIA Study Results

argenx SE's ALKIVIA Trial Achieves Primary Endpoint Success

argenx ALKIVIA Study Achieves Positive Results

Halozyme Reports Increased Net Income in Q2

Investors Increase Exposure to International Equities

argenx Acquires Forte Biosciences for $2.2 Billion

8/17 12:30

Argenx Shares Rise 16.6%

Argenx is up 16.6%, or…

8/17 10:30

Argenx Shares Rise 14.9%

Argenx is up 14.9%, or…

8/17 06:30

Zai Lab Partners with argenx for Strategic Collaboration

Zai Lab (ZLAB) and argenx…

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。